OncoMatch/Clinical Trials/NCT05874401
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Is NCT05874401 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Trilaciclib and Topotecan for extensive-stage small-cell lung cancer.
Treatment: Trilaciclib · Topotecan — This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
ES-SCLC
Prior therapy
Must have received: platinum-based chemotherapy — first-line
First-line regimen must have been a platinum-containing combination
Cannot have received: topoisomerase I inhibitor (topotecan, trilaciclib)
History of topotecan (or other topoisomerase I inhibitor) or trilaciclib treatment for SCLC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05874401 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase I inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages